PATHOLOGY & ONCOLOGY RESEARCHVol. 5 No. 3, 1999

 Article

Serum levels of S-100 protein and 5-S-cysteinyldopa as markers of melanoma progression

Teodóra BÁNFALVI1, Katalin GILDE1, Mariann BOLDIZSÁR2, Tibor KREMMER2, Szabolcs OTTÓ3

1Department of Dermatology, National Institute of Oncology, Budapest, Hungary
2Department of Biochemistry, National Institute of Oncology, Budapest, Hungary
3Central Clinical Laboratory, National Institute of Oncology, Budapest, Hungary

 

Serum S-100 protein is widely used as a marker of melanoma and since 5-S-cysteinyldopa (5-S-CD) is a precursor of melanin its serum and urinary levels can reflect melanoma progression. In this study we examined the concentration changes of serum S-100 protein and 5-S-CD in 252 melanoma patients of different clinical stages. Serum samples were taken from 252 melanoma patients at 860 times, from June 1996 to July 1998. The serum S-100 protein was measured by the immunoluminometric assay, levels of 5-S-CD was determined by HPLC. The value of S-100 protein in patients with primary melanoma (0.11m mg/l) and in patients without symptoms (0.15 m mg/l) ranged around the normal level (0.01–0.12 m mg/l). There was a significant difference between the values of patients with or without symptoms. There was a similarly significant difference between the S-100 values of clinical Stage I (0.11 mg/l) and Stage III (2.91 mg/l) as well as between those of clinical Stage II (0.47 mg/l) and Stage III (2.91 mg/l), respectively. Analyzing the values of patients with symptoms we observed significant difference between the S-100 protein values of patients with primary tumor and those with solitary or multiple distant metastases. In case of 5-S-CD significant difference was found between clinical Stage I and III as well as clinical Stage II and III. Furthermore, there was a significant difference between the mean marker values of patients with primary tumor, lymph node, lung metastasis and clinical stage III. Pathology & Oncology Research, Vol 5, Nr 3, 218-222, 1999

Key words: melanoma; S-100 protein; 5-S-cysteinyldopa


Received: Jul 9, 1999; accepted: Aug 5, 1999
Correspondence: Teodóra BÁNFALVI, Department of Dermatology, National Institute of Oncology, Ráth György u. 7-9. Budapest H-1122, Hungary; Tel: 36-1-224-8600, Fax: 36-1-224-8620; E-mail: banfalvi@oncol.hu

Click here to get the full-text version in PDF!
ad